Vivoryon Therapeutics N.V.
VVY.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €52 | €205 | €227 | €380 |
| - Cash | €9 | €19 | €27 | €15 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €43 | €187 | €201 | €366 |
| Revenue | €0 | -€4 | €0 | €11 |
| % Growth | 100% | – | -100% | – |
| Gross Profit | -€0 | -€3 | -€0 | €9 |
| % Margin | – | 85.5% | – | 83.9% |
| EBITDA | -€20 | -€28 | -€28 | -€12 |
| % Margin | – | 783.2% | – | -111.8% |
| Net Income | -€21 | -€28 | -€28 | -€13 |
| % Margin | – | 782.9% | – | -117.6% |
| EPS Diluted | -0.79 | -1.12 | -1.28 | -0.63 |
| % Growth | 29.5% | 12.5% | -103.2% | – |
| Operating Cash Flow | -€19 | -€22 | -€22 | -€11 |
| Capital Expenditures | -€0 | -€1 | -€0 | -€0 |
| Free Cash Flow | -€19 | -€22 | -€22 | -€11 |